SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. – RPRX

NEW YORK, July 17, 2017 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Repros Therapeutics, Inc. (“Repros” or the “Company”)

RPRX, -33.49%

   Such investors are advised to contact Robert S. Willoughby at or 888-476-6529, ext. 9980.

The investigation concerns whether Repros and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On July 17, 2017, Repros announced receipt of preliminary feedback from the U.S. Food and Drug Administration (“FDA”) on the Company’s clinical development program for Proellex, its oral delivery mechanism for telapristone acetate.  Repros advised investors that “[t]he Proellex program will remain on partial clinical hold, and based upon the FDA’s review of all the existing liver function safety data, the FDA has indicated that the Company will be required to compile a large pre-approval safety data base to support future development.”  Repros stated that “a much larger clinical trial, with associated time and cost requirements, would be necessary.” 

On this news, Repros’s share price has fallen more than 30% during intraday trading on July 17, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See

CONTACT:Robert S. Willoughby
Pomerantz LLP

View original content:–rprx-300489102.html

SOURCE Pomerantz LLP

Copyright (C) 2017 PR Newswire. All rights reserved

Go to Source